Intravenous (IV) Solutions

Global Intravenous (IV) Solutions Market to Reach US$21.7 Billion by 2030

The global market for Intravenous (IV) Solutions estimated at US$14.1 Billion in the year 2024, is expected to reach US$21.7 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Parenteral Nutrition, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$15.1 Billion by the end of the analysis period. Growth in the Peripheral Parenteral Nutrition segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.5 Billion While China is Forecast to Grow at 9.0% CAGR

The Intravenous (IV) Solutions market in the U.S. is estimated at US$5.5 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.4% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Global Intravenous (IV) Solutions Market - Key Trends & Drivers Summarized

Intravenous (IV) solutions are a cornerstone of modern medical treatment, providing a direct method of delivering fluids, medications, and nutrients into the bloodstream. These solutions are crucial for maintaining fluid balance, electrolyte levels, and for delivering drugs and essential nutrients in situations where oral intake is not possible or insufficient. IV solutions are categorized based on their composition and purpose, such as crystalloids, colloids, blood products, and nutrient solutions. Crystalloids, like saline and lactated Ringer`s, are the most commonly used for fluid resuscitation and maintenance. Colloids, including albumin and dextran, are used for volume expansion. Nutrient solutions, which provide carbohydrates, proteins, and fats, are vital for patients requiring parenteral nutrition. The precise composition and administration of these solutions are tailored to meet the specific needs of patients, making them indispensable in various medical settings, from emergency care to chronic disease management.

The growth in the intravenous (IV) solutions market is driven by several factors. The increasing prevalence of chronic diseases such as diabetes, cancer, and gastrointestinal disorders has heightened the demand for IV therapy, which is often essential for managing these conditions. The aging population, with its higher susceptibility to dehydration and nutrient deficiencies, further propels the market, as elderly patients frequently require IV solutions for hydration and nutritional support. Additionally, the rise in surgical procedures and emergency care incidences necessitates a reliable supply of IV solutions for perioperative care and acute treatment. Technological advancements in IV equipment and the development of specialized formulations have expanded the use of IV therapy in various clinical settings. Moreover, the growing focus on home healthcare and outpatient services has increased the demand for portable and easy-to-administer IV solutions, providing patients with greater flexibility and convenience in their treatment regimens. These factors collectively underscore the robust expansion and critical importance of the IV solutions market in the healthcare industry.

Technological advancements and rigorous quality standards have significantly improved the safety and efficacy of IV solutions. Modern IV therapy incorporates advancements such as improved sterility practices, enhanced packaging to prevent contamination, and the development of pre-mixed solutions to minimize preparation errors. Innovations like smart infusion pumps have revolutionized the administration of IV solutions, allowing for precise control over infusion rates and volumes, reducing the risk of over-infusion or under-infusion. Additionally, the integration of electronic health records (EHR) with infusion systems ensures accurate documentation and monitoring of IV therapy, enhancing patient safety. The pharmaceutical industry continues to innovate by developing new formulations and combinations of IV solutions to address complex medical conditions, improving patient outcomes and expanding the therapeutic applications of IV therapy.

SCOPE OF STUDY:

The report analyzes the Intravenous (IV) Solutions market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Parenteral Nutrition, Peripheral Parenteral Nutrition); Nutrient (Single Dose Amino Acids, Vitamins & Minerals, Carbohydrates, Parenteral Lipid Emulsion, Other Nutrients)

Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 82 Featured) -

• Amanta Healthcare Ltd.
• Anhui Medipharm Co., Ltd.
• AxaParenterals Ltd.
• B. Braun Melsungen AG
• Baxter International Inc.
• Becton, Dickinson and Company
• Fresenius Kabi AG
• Grifols, S.A.
• ICU Medical, Inc.
• JW Life Science
• Otsuka Pharmaceutical Co. Ltd.
• Pfizer Inc.
• Salius Pharma Private Limited.
• Vifor Pharma Management Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.